亚洲v日韩v精品v无码专区_精选国产av精选一区二区_欧美日本一道高清国产_夜夜欢天天干_亚洲国产一成人久久精品,天天操天天干天天摸天天日天天插天无想,亚洲国产欧美日韩在线,靠靠操操网

US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
To-be Listed
Name▼
/
Code▼
 Industry Offer Price Lot Size Entry Fee Closing Date
Grey Market Date▼
Listing Date▲
Haitian Flav
03288.HK		 Food Additives 35-36.3 100 3,667 2025/06/16 2025/06/18 2025/06/19
Sanhua
02050.HK		 Electrical Components & Equipment 21.21-22.53 100 2,276 2025/06/18 2025/06/20 2025/06/23
Bayzed Health
02609.HK		 Health Care Services 4.22-6.75 600 4,091 2025/06/18 2025/06/20 2025/06/23
TransThera-B
02617.HK		 Biotechnology - Pharmaceuticals 13.15 500 N/A 2025/06/18 2025/06/20 2025/06/23
Summary
Founded in 1993 and headquartered in Zhejiang Province, we are a biopharmaceutical company in China with over 30 years of proven track record in the R&D, manufacturing and commercialization of biopharmaceutical products and medical devices. We focus on four large and fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Collectively, these four therapeutic areas accounted for 51.5% of the total pharmaceutical sales in China in 2023, and outpaced the broader Chinese pharmaceutical industry from 2018 to 2023, a trend which is expected to continue in the near future, according to CIC.

Centred around these therapeutic areas, we have built a diversified product portfolio comprising eight marketed products, including China’s first recombinant human bone morphogenetic protein-2 (“rhBMP-2”) bone repair material, Guyoudao, and over ten product candidates, including the first semaglutide biosimilar in China to have obtained an IND approval and filed an NDA, JY29-2, as of the Latest Practicable Date. Our strategy starts by identifying therapeutic targets with market potential in our focused areas. Once the targets are identified, we pursue the development of China’s innovative and first follow-on products, leveraging our established R&D platforms, manufacturing capabilities, and sales and distribution network in China.

Our Portfolio and Pipeline

Our marketed product portfolio includes one drug-device combination, two biological products, and five chemical drugs in orthopedics, oncology and hematology. Among them, several of our products are domestically developed first-to-market products and maintain a competitive position in their respective product category in terms of market share as measured by revenue in 2023. Notably, our drug-device combination product, Guyoudao, is the first product containing bone repair material with rhBMP-2 approved for sale in China, and ranked first by sales revenue in China’s bone repair material market in 2023, according to CIC. We acquired Guyoudao from Hangzhou Huadong Medicine Group Co., Ltd. (杭州華東醫(yī)藥集團有限公司) in 2010 recognizing its promising prospects, and it generated a significant portion of our revenue during the Track Record Period. For details of the transaction, please see “Business — Our Products — Orthopedic Product.” Revenue generated from all of our marketed products accounted for 87.6%, 93.8%, 91.5% and 87.9% of our total revenue for the years ended December 31, 2021, 2022, 2023 and the six months ended June 30, 2024, respectively.

Beyond our offerings in orthopedics, oncology and hematology, we have nearly 18 years of experience in metabolic disease drug development. We initiated our research into the agonists to GLP-1 receptor, a key therapeutic target in metabolic diseases, in 2005. Based on our peptide drug technology platform, we developed the first biosimilar candidate to liraglutide (a GLP-1 receptor agonist) to have obtained the IND approval in China. For details of our peptide drug technology platform, see “Business — Research and Development — Our Product Development Platforms.” We transferred this product candidate to Zhongmei Huadong between 2017 and 2019 to raise funds for the development of our other product pipelines at that time. The terms and conditions for such transfers were arrived at after arm’s length negotiation and are in line with the industry average for similar arrangements. In p a r t i c u l a r, the transfer fees were determined based on the appraised value of the transferred technologies and intellectual properties assessed by an independent valuer. For details, please refer to the paragraphs headed “— Collaboration Arrangements — Transfer Agreements of Liluping (Liraglutide) with Zhongmei Huadong” in this section. Through our collaborative efforts with Zhongmei Huadong, this candidate became the first liraglutide biosimilar approved for the treatment of T2DM as well as obesity and overweight in China in March and June 2023, respectively.

Benefiting from the R&D experience we accumulated, we further developed another GLP-1 receptor agonist, JY29-2. JY29-2 is a semaglutide biosimilar and we are developing it under the brand name of Jiyoutai (吉優(yōu)泰) for the treatment of type 2 diabetes mellitus (“T2DM”), and under the brand name of Jikeqin (吉可親) for the treatment of obesity and overweight. JY29-2 (Jiyoutai) is the first semaglutide biosimilar in China to have obtained the IND approval, completed a Phase III clinical trial, and submitted an NDA. In January 2024, we obtained the IND approval from the NMPA to evaluate our JY29-2 (Jikeqin) for the treatment of obesity and overweight. Semaglutide products recorded global sales of US$20.6 billion in 2023 by generic name, making it the top three best-selling drugs worldwide in 2023. However, the market size of semaglutide for the treatment of T2DM, overweight and obesity could potentially be limited by alternative prevention and treatment methods for such indications and medication treatment is used only for a portion of the total T2DM, overweight and obesity population. See “Risk Factors — Risks Relating to the Development of Our Product Candidates — The market opportunities for our product candidates may be smaller than we anticipate, which could render some product candidates less profitable than expected even if commercialized.”

Source: Jiuyuan Gene (02566) Prospectus (IPO Date : 2024/11/20)
Listing Market MAIN
Industry Pharmaceuticals
Background H Shares
Major Business Area N/A
Corporate Information
Substantial Shareholders Hu Kaijun & Associates (17.16%)
Hangzhou Huasheng Pharmaceutical Group Co., Ltd. (13.24%)
Corporacion Quimico-farmaceutica Esteve, Sociedad Anonima (12.22%)
Insigma Technology Co., Ltd. (9.99%)
Yang Loon Chun (8.15%)
Hangzhou Investment Holdings Co., Ltd. (7.10%)
Hangzhou Heda Jinyuan Equity Investment Fund Partnership Enterprise (Limited Partnership) (5.05%)
Directors Fu Hang (Chairman and General Manager and Executive Director)
Zhou Wei (Deputy General Manager and Executive Director)
Albert Esteve Cruella (Non-Executive Director)
Fei Junjie (Non-Executive Director)
Ma Honglan (Non-Executive Director)
Wu Shihang (Non-Executive Director)
Ho Mei Yi (Independent Non-Executive Director)
Zhou Demin (Independent Non-Executive Director)
Zhou Zhihui (Independent Non-Executive Director)
Company Secretary Ho Wing Nga
Huang Xiu
Principal Bankers Bank Of China Bank
China Merchants Bank
China CITIC Bank Corporation Limited
Solicitors Hogan Lovells
Cooley HK
Zhejiang T&C Law Firm
Auditors Ernst & Young
Registered Office 46/F., Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong
Share Registrars Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No (852) 2862-8628
Internet Address https://www.china-gene.com
Email Address [email protected]
Tel No (86 571) 8691-0099
Fax No (86 571) 8691-1688
 
SITEMAP
Email: [email protected]
AASTOCKS.COM LIMITED (阿斯達克網(wǎng)絡(luò)信息有限公司) All rights reserved.
Disclaimer
You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright ? 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.